Which stages of therapeutic antibody development do you cover—from discovery to production?

We cover the full workflow, from antibody discovery to engineering and optimization, developability assessment, expression and purification, and research to preclinical production, including stable cell line development for scale-up.

Which antibody discovery platforms do you offer?

We offer three platforms: phage display service, single B cell sorting service, and hybridoma service.

Can you support difficult targets or complex antigens?

Yes. We routinely support challenging targets and complex antigens, and we adapt strategy and assay design to match target-specific constraints.

Do you support antibody engineering formats such as bispecifics or ADCs?

Yes. We support advanced formats including bispecific antibodies services and antibody–drug conjugates services (ADCs).

Do you address affinity maturation, humanization, and developability?

Yes. We support affinity maturation service, humanization service, and developability assessment as part of an integrated optimization strategy.

How transparent is progress tracking and data reporting?

Progress tracking is fully transparent. You receive clear, structured data reports as project deliverables, and you have dedicated support to review results and next steps.

Are there cost efficiencies when combining multiple services?

Yes. Combining multiple services into a single integrated program typically creates cost efficiencies, reduces handoffs, and shortens timelines.

Can you support multiple antibody programs in parallel?

Yes. We can support multiple programs in parallel, with dedicated project structure and clear reporting for each program.

Do you act as a true development partner rather than a transactional CRO?

Yes. We operate as a true development partner, with expert guidance, proactive project management, and a strategy built around your program’s success—not just task execution.

Which AI-powered antibody engineering services do you provide?

Our AI-enabled antibody engineering services include AI-powered affinity maturation service, AI-driven antibody humanization service, AI-driven antibody developability assessment service, and epitope mapping service to help you optimize candidates faster and de-risk key decisions.

Therapeutic Antibody Services

Built for end-to-end monoclonal antibody development

From candidate antibody design to production

Expert in challenging projects

Zero-risk approach

One partner for your end-to-end therapeutic antibody development project

Maximize your chances of reaching the clinic with one partner offering an end-to-end therapeutic antibody services paired with customized strategies: from complex antigen design service to antibody production.

From complex antigen design to antibody production

Antibody discovery services

- Fully human antibodies
- Fast lead generation : 1 month
- No Win–No Fee & IP free

Antibody characterization services

- Full profiling toolbox with 12 characteristics
- Assays tailored to need
- AI epitope/paratope mapping

Custom recombinant antibody production

- Fully customizable
- Scalable : µg → kg
- Any format (IgG, Fab, scFv, VHH, bispecifics…)

Antibody optimization services

- Combine AI-guided with wet lab
- Boost affinity & developability
- Short turnaround: 6 weeks for affinity maturation, 4 weeks for humanization

Antibody engineering

- Design for complex formats (bispécific, ADC, Car-T cell)
- Stage-gated execution and zero-risk approach

Custom cell line development

- High titer, predictable yield
- Proof of monoclonality (VIPS)
- Royalty-free

Turn your antibody program into results with dedicated expert support

You get dedicated support from PhD-level experts who stay focused on your project’s success. This integrated support keeps your therapeutic antibody development tightly aligned with your goals at every step. Every strategy is fully tailored to your constraints, so your custom antibody development is built to fit your reality. Our experienced project managers are used to running complex antibody programs, including challenging targets and advanced formats.
It helps you move faster through key milestones and shorten timelines and it de-risks your program by keeping the focus on the most promising candidates.

Contact our PhD-level experts

Therapeutic antibody services with risk control included

Milestone-based delivery keeps the program on track with clear, validated outcomes at each step. You de-risk your monoclonal antibody program through clear decision gates and validated deliverables.

Go/No Go

Go/No-Go milestones at every key stage let you validate progress early and move your lead candidate into bioproduction with confidence.

No win, no fee

No win, no fee means you only pay when the agreed results are delivered.

A minimum yield is guaranteed

A minimum yield is guaranteed, you can plan downstream steps without uncertainty.

Quality system

Our ISO 9001:2015 and ISO 14001:2015 certified quality system ensures robust processes and consistent product quality.

IP Free: your innovation stays your property

You retain full ownership of the antibody, sequences, and project data generated throughout the program. All deliverables are royalty-free, with no downstream claims or licensing constraints. You can move forward to development, manufacturing, or partnering without restrictions.